Carboplatino u olaparib para el cáncer de próstata por deficiencia de BrcA (COBRA)
Un estudio abierto, multicéntrico de fase II para comparar la eficacia de carboplatino como primera línea seguido de olaparib de segunda línea versus olaparib como primera línea seguido de carboplatino de segunda línea en el tratamiento de pacientes con cáncer de próstata resistente a la castración que contiene recombinación homóloga Deficiencia
This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use olaparib or carboplatin as initial therapy with crossover to the alternate or second-line drug after first progression for patients with tumors containing BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L inactivating mutations.
Participants are randomized (1:1) and receive either carboplatin (AUC 5, IV) every 21 days, first or olaparib taken orally (300 mg), twice daily in 28 day cycles, until intolerance, complete response, or progression by Prostate Cancer Working Group 3 (PCWG3) criteria.
Participants then crossover from the first-line therapy to the second-line therapy with the opposite study medication and receive treatment to intolerance or progression (whichever is first). Enrolled participants will be allowed to crossover to second line therapy if they continue to meet initial eligibility criteria, and at least three weeks have elapsed since last administration of either carboplatin or olaparib. Throughout the study, safety and tolerability will be assessed. Progression will be evaluated with bone scan, CT of the abdomen/pelvis, or MRI and PSA as per PCWG3 criteria.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Study General Trial Over-view
This study is designed to help better understand treatment options compared to standard therapies for patients who have targeted DNA repair mutations and metastatic castrate resistant prostate cancer (mCRPC).
Cancer therapies are aimed at finding a way to kill the cancer cells while causing minimal damage to normal (non-cancer) cells. This often works because cancers cells grow faster than many normal cells, many treatments are aimed at to take advantage of that difference. One of the ways to do this is to damage the DNA of these more rapidly growing cells. However, if the cells have a way of repairing that damage then therapies may not work as well. Some research shows that when specific changes or mutations occur in the genes involved with repairing DNA damage, resulting cancers have responded well to drugs which damage DNA.
Olaparib is known as a PARP inhibitor and is standard of care therapy for men with BRCA altered mCRPC. Carboplatin is a synthetic antineoplastic agent which has been used in the treatment of solid tumors and BRCA related cancers. When mutations occur in critical DNA-repair genes, research has found that treatment with carboplatin is also effective.
This research is being done to determine the response of mCRPC in patients with DNA repair mutations to treatment with olaparib compared to carboplatin. This study will test whether giving one drug or the other a has a better response.
Patients wishing to participate in this study are screened for safety and health eligibility before enrolling.
This study is enrolling 100 male participants total, from across the VAMC nationally who have the following:
- Metastatic castration-resistant prostate cancer (mCRPC)
- Cancer that has gotten worse, after any number of first-line treatments
- Mutations in DNA-repair genes discovered as part of a patient's routine care.
Once eligibility is determined, enrolled participants are randomized into one of two groups:
- Group A will start with carboplatin (IV) first, given every 21 days, then have the option to switch to the second treatment with olaparib taken daily, (orally) with cycles of every 28 days.
- Group B will start with olaparib first, taken (orally), with 28 day cycles, then have the option to switch to the second treatment with carboplatin (IV) every 21 days.
Both study drugs in this trial are currently FDA approved, and are prescribed at the participating VAMC clinical sites per institutional guidelines. Carboplatin given in IV is also given as prescribed at the participating VAMC, and administered per institutional guidelines.
Participants are monitored for health and body function, cancer progression, toxicity and life quality at every visit during the trial and at an end of treatment visit (28 days after completion of the trial or after withdrawal). For participants who respond well to treatment during the trial, additional treatment cycles may be added and the study can be extended. Participants who experience intolerable toxicity, cancer progression, or whose doctors decide to change treatment, will either be switched to the opposite study drug or withdrawn from the study.
This important trial is designed to compare response rate and duration of response using carboplatin compared to olaparib in patients who have mCRPC which contains DNA repair gene mutations.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Makayla L DeJong, BA
- Número de teléfono: (206) 277-4527
- Correo electrónico: Makayla.Dejong@va.gov
Copia de seguridad de contactos de estudio
- Nombre: Robert B Montgomery, MD
- Número de teléfono: (206) 277-6878
- Correo electrónico: Robert.Montgomery@va.gov
Ubicaciones de estudio
-
-
California
-
West Los Angeles, California, Estados Unidos, 90073
- Reclutamiento
- VA Greater Los Angeles Healthcare System, West Los Angeles, CA
-
Contacto:
- Matthew Rettig, MD
- Número de teléfono: 4761 310-478-3711
- Correo electrónico: matthew.rettig@va.gov
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Reclutamiento
- Rocky Mountain Regional VA Medical Center, Aurora, CO
-
Contacto:
- Daniel Bowles
- Correo electrónico: Daniel.bowles@va.gov
-
-
District of Columbia
-
Washington D.C., District of Columbia, Estados Unidos, 20422-0001
- Reclutamiento
- Washington DC VA Medical Center, Washington, DC
-
Contacto:
- Joao Ascensao, MD
- Número de teléfono: 202-745-8134
- Correo electrónico: Joao.Ascensao@va.gov
-
-
Florida
-
Bay Pines, Florida, Estados Unidos, 33744-0000
- Terminado
- Bay Pines VA Healthcare System, Pay Pines, FL
-
Orlando, Florida, Estados Unidos, 32827
- Reclutamiento
- Orlando VA Medical Center, Orlando, FL
-
Contacto:
- Priya Gopalan, MD
- Correo electrónico: priya.gopalan@va.gov
-
-
Georgia
-
Decatur, Georgia, Estados Unidos, 30033
- Reclutamiento
- Atlanta VA Medical and Rehab Center, Decatur, GA
-
Contacto:
- Wayne Harris, MD
- Número de teléfono: 206147 404-321-6111
-
-
Idaho
-
Boise, Idaho, Estados Unidos, 83702
- Reclutamiento
- Boise VA Medical Center, Boise, ID
-
Contacto:
- Paul Montgomery, MD
- Correo electrónico: Paul.montgomery@va.gov
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60612
- Terminado
- Jesse Brown VA Medical Center, Chicago, IL
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48105
- Reclutamiento
- VA Ann Arbor Healthcare System, Ann Arbor, MI
-
Contacto:
- Ramnath Nithya, MD
- Número de teléfono: 734-845-5800
- Correo electrónico: Nithya.Ramnath@va.gov
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55417-2309
- Reclutamiento
- Minneapolis VA Health Care System, Minneapolis, MN
-
Contacto:
- Mark Klein
- Correo electrónico: Mark.Klein@va.gov
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64128
- Reclutamiento
- Kansas City VA Medical Center, Kansas City, MO
-
Contacto:
- Bruce Montgomery
- Número de teléfono: 206-277-6878
-
-
New York
-
New York, New York, Estados Unidos, 10010
- Reclutamiento
- Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY
-
Contacto:
- Daniel Becker, MD
- Número de teléfono: 212-731-6463
- Correo electrónico: daniel.becker2@va.gov
-
The Bronx, New York, Estados Unidos, 10468-3904
- Terminado
- James J. Peters VA Medical Center, Bronx, NY
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27705-3875
- Reclutamiento
- Durham VA Medical Center, Durham, NC
-
Contacto:
- Rhonda L Bitting, MD
- Número de teléfono: 5441 919-286-6180
- Correo electrónico: rhonda.bitting@va.gov
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97239
- Reclutamiento
- VA Portland Health Care System, Portland, OR
-
Contacto:
- Julie Graff, MB
- Número de teléfono: 503-220-8262
- Correo electrónico: julie.graff@va.gov
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19106
- Reclutamiento
- Philadelphia MultiService Center, Philadelphia, PA
-
Contacto:
- Kyle Robinson, MD
- Número de teléfono: 2371 215-823-5800
- Correo electrónico: kyle.robinson3@va.gov
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98108-1532
- Reclutamiento
- VA Puget Sound Health Care System Seattle Division, Seattle, WA
-
Investigador principal:
- Robert B. Montgomery, MD
-
Contacto:
- Robert B Montgomery, MD
- Número de teléfono: (206) 277-6878
- Correo electrónico: Robert.Montgomery@va.gov
-
-
Wisconsin
-
Madison, Wisconsin, Estados Unidos, 53705-2254
- Reclutamiento
- William S. Middleton Memorial Veterans Hospital, Madison, WI
-
Contacto:
- David Kosoff
- Correo electrónico: david.kosoff@va.gov
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Signed study informed consent form (ICF) and HIPAA authorization form
-
Diagnosis of prostate cancer (pure small-cell histology or pure high-grade neuroendocrine histology are excluded; neuroendocrine differentiation is allowed)
-
Ongoing gonadal androgen deprivation therapy with gonadotropin-releasing hormone (GnRH) analogues, antagonists or orchiectomy. Patients who have not had an orchiectomy must be maintained on effective GnRH analogue/antagonist therapy
-
mCRPC as defined by serum testosterone < 50 nanograms per milliliter (ng/ml) for patients on GnRH analogues or antagonists) and at least one of the following:
- Prostate-specific antigen (PSA) level of at least 2 nanograms per milliliter (ng/ml) that has risen on at least 2 successive occasions at least 1 week apart
- Evaluable disease progression by modified RECIST 1.1 (Response Evaluation Criteria in Solid Tumors)
- Progression of metastatic bone disease on bone scan, CT or MRI with > 2 new lesions
-
Prior therapy with abiraterone acetate, enzalutamide, apalutamide, or darolutamide
-
Eastern Cooperative Oncology Group (ECOG) Performance Status of < 2 (see Appendix 3, ECOG Grading Scale)
-
Results of previous standard DNA testing, or previous research testing, which confirms RAD51B, RAD51C, RAD51D, or RAD54L mutations (see Introduction, Section 2 for study design and previous research on targeted therapy) from primary, metastatic tumor or circulating tumor DNA, or pathogenic/likely pathogenic germline variant as assessed by a CLIA certified laboratory level assay for DNA sequencing.
-
Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below:
- Hemoglobin > 10.0 grams per deciliter (g/dL)
- Absolute neutrophil count (ANC) > 1.5 x 109/liter (L)
- Platelet count > 100 x 109/L
- Total bilirubin < 1.5 x institutional upper limit of normal (ULN)
- Aspartate aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT) / Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT) < 2.5 x institutional upper limit of normal unless liver metastases are present in which case, they must be < 5x ULN
- Patients must have creatinine clearance estimated using the Cockcroft-Gault equation of >51 mL/min: Estimated creatinine clearance =(140-age [years]) x weight (kg)/(serum creatinine (mg/dL) x 72)
Exclusion Criteria:
- Currently receiving active therapy for other neoplastic disorder(s)
- Concurrent enrollment in another clinical investigational drug or device study
- Histologic evidence of small cell carcinoma (morphology alone - immunohistochemical evidence of neuroendocrine differentiation without morphologic evidence is not exclusionary)
- Prior treatment with platinum, mitoxantrone or PARP inhibitor for castration resistant prostate cancer
- Known parenchymal brain metastasis
- Active or symptomatic viral hepatitis or chronic liver disease AST or ALT > 2.5 x ULN or total bilirubin > ULN (unless Gilbert's syndrome is the etiology of hyperbilirubinemia)
- Subjects with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of MDS/AML
- Concomitant use of known strong CYP3A inhibitors (e.g. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (e.g. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting olaparib is 2 weeks
- Concomitant use of known strong (e.g. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate CYP3A inducers (e.g. bosentan, efavirenz, modafinil). The required washout period prior to starting olaparib is 5 weeks for phenobarbital and 3 weeks for other agents
- Subjects unable to swallow orally administered medication and subjects with gastrointestinal disorders likely to interfere with absorption of the study medication
- Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association (NYHA) Class II-IV heart disease or cardiac ejection fraction measurement of < 35 % at baseline
- Treatment with an investigational therapeutic within 30 days of Cycle-1
- Presence of dementia, psychiatric illness, and/or social situations limiting compliance with study requirements or understanding HIPAA authorization and/or giving of informed consent
- Any condition(s), medical or otherwise, which, in the opinion of the Investigators, would jeopardize either the patient or the integrity of the data obtained
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Investigación de servicios de salud
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Comparador activo: Treatment Arm 1 - Carboplatin to Olaparib
Participants are administered carboplatin AUC 5 IV first, which is administered Cycle-1, Day-1, and then every 21 days as first line therapy. For second line (crossover), olaparib is prescribed and taken orally at home, twice daily, 300 mg in 28 day cycles. |
Chemotherapy FDA approved drug used to treat: ovarian, lung, head and neck cancers. It is sometimes used in combination with other medications or off-label use to treat other metastatic cancers.
Otros nombres:
Olaparib is a targeted therapy drug that is used for mCRPC and is approved by the FDA for this use.
Otros nombres:
|
|
Comparador activo: Treatment Arm 2 - Olaparib to Carboplatin
Participants are prescribed olaparib which is taken orally at home, twice daily, 300 mg in 28 day cycles, as first line therapy. For second line (crossover), carboplatin is administered AUC 5 IV every 21 days thereafter. |
Chemotherapy FDA approved drug used to treat: ovarian, lung, head and neck cancers. It is sometimes used in combination with other medications or off-label use to treat other metastatic cancers.
Otros nombres:
Olaparib is a targeted therapy drug that is used for mCRPC and is approved by the FDA for this use.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Progression-free survival (PFS-1L) defined as the time interval between randomization and first documented disease progression or death due to any cause reported during, or after, first-line treatment
Periodo de tiempo: Through duration of the study, up to 100 weeks
|
Progression free survival (PFS) by bone scan or measurable disease, Response Evaluation Criteria in Solid Tumors (RECIST 1.1) to initial therapy (PFS-1L) with either study drug |
Through duration of the study, up to 100 weeks
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Time interval between randomization and second documented disease progression during or after second-line or death (due to any cause)
Periodo de tiempo: Through duration of the study, up to 100 weeks
|
Progression-free survival combined, a composite endpoint defined as the time interval between randomization and second documented disease progression reported during or after second-line or death due to any cause |
Through duration of the study, up to 100 weeks
|
|
PSA measurements/response
Periodo de tiempo: Through duration of the study, up to 100 weeks
|
To assess PSA response to initial therapy with carboplatin vs. olaparib |
Through duration of the study, up to 100 weeks
|
|
PSA measurements/response
Periodo de tiempo: Through duration of the study, up to 100 weeks
|
To assess PSA response duration to second line therapy with olaparib vs carboplatin |
Through duration of the study, up to 100 weeks
|
|
Grade 3 and 4 toxicities in first and second-line setting
Periodo de tiempo: Through duration of the study, up to 100 weeks
|
To assess Grade 3 and 4 toxicities for each regimen in the first- and second-line setting |
Through duration of the study, up to 100 weeks
|
|
To assess cost effectiveness of carboplatin versus olaparib for the treatment of castration-resistant metastatic prostate cancer
Periodo de tiempo: Through duration of the study, up to 100 weeks
|
To assess cost effectiveness of carboplatin versus olaparib for the treatment of castration-resistant metastatic prostate cancer |
Through duration of the study, up to 100 weeks
|
Otras medidas de resultado
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Exploratory Objective - PFS
Periodo de tiempo: Through duration of the study, up to 100 weeks
|
To assess the PFS of patients who receive olaparib versus patients who receive carboplatin during the second-line of treatment (PFS-2L) |
Through duration of the study, up to 100 weeks
|
|
Exploratory Objective - objective response rate
Periodo de tiempo: Through duration of the study, up to 100 weeks
|
To assess the objective response rate in patients who receive olaparib versus patients who receive carboplatin during second-line of treatment. |
Through duration of the study, up to 100 weeks
|
|
Exploratory Objective- objective duration of response
Periodo de tiempo: Through duration of the study, up to 100 weeks
|
To assess the objective duration of response in patients who receive olaparib versus patients who receive carboplatin during second-line of treatment. |
Through duration of the study, up to 100 weeks
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Robert B. Montgomery, MD, VA Puget Sound Health Care System Seattle Division, Seattle, WA
- Investigador principal: Maneesh Jain, MD, Washington DC VA Medical Center, Washington, DC
- Investigador principal: Phoebe Tsao, MD MSc, VA Ann Arbor Healthcare System, Ann Arbor, MI
- Investigador principal: Ryan Burri, MD, Bay Pines VA Healthcare System, Pay Pines, FL
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades Genitales
- Enfermedades del Sistema Nervioso
- Neoplasias Genitales Masculinas
- Neoplasias urogenitales
- Neoplasias por sitio
- Neoplasias
- Enfermedades Genitales Masculinas
- Enfermedades prostáticas
- Enfermedades urogenitales masculinas
- Enfermedades Neuromusculares
- Enfermedades Genéticas Congénitas
- Enfermedades del Sistema Nervioso Periférico
- Enfermedades neurodegenerativas
- Anomalías congénitas
- Trastornos Heredodegenerativos, Sistema Nervioso
- Malformaciones del Sistema Nervioso
- Polineuropatías
- Enfermedades y anomalías congénitas, hereditarias y neonatales
- Neoplasias prostáticas
- Neuropatías sensoriales y autonómicas hereditarias
- Anemia Fanconi, Grupo de complementación D1
- Fanconi Anemia, Complementation Group N
- Químicos orgánicos
- Complejos de coordinación
- Carboplatino
- olaparib
Otros números de identificación del estudio
Otros números de identificación del estudio
- ONCA-009-18F
- CX-18-006 (Otro número de subvención/financiamiento: Veterans Affairs CSR&D Merit Review Award)
- 19-08 (Otro identificador: VA CIRB)
- 01783 (Otro identificador: MIRB (LSI))
- 01781 (Otro identificador: MIRB (National Chair))
- 1I01CX001963-01 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .